JP2019527714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527714A5 JP2019527714A5 JP2019507125A JP2019507125A JP2019527714A5 JP 2019527714 A5 JP2019527714 A5 JP 2019527714A5 JP 2019507125 A JP2019507125 A JP 2019507125A JP 2019507125 A JP2019507125 A JP 2019507125A JP 2019527714 A5 JP2019527714 A5 JP 2019527714A5
- Authority
- JP
- Japan
- Prior art keywords
- chain fatty
- fatty acids
- individual
- short
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004666 short chain fatty acids Chemical class 0.000 claims 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 21
- 235000021391 short chain fatty acids Nutrition 0.000 claims 20
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 14
- 150000002148 esters Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000023275 Autoimmune disease Diseases 0.000 claims 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 8
- 210000002429 large intestine Anatomy 0.000 claims 5
- 235000013305 food Nutrition 0.000 claims 4
- 235000019260 propionic acid Nutrition 0.000 claims 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 210000000813 small intestine Anatomy 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 239000008107 starch Substances 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 235000021588 free fatty acids Nutrition 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 agents Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical group 0.000 claims 1
- 235000021434 dietary agent Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical group 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903143A AU2016903143A0 (en) | 2016-08-10 | Metabolites for treatment of autoimmune disease | |
| AU2016903143 | 2016-08-10 | ||
| PCT/AU2017/050845 WO2018027274A1 (en) | 2016-08-10 | 2017-08-10 | Metabolites for treatment and prevention of autoimmune disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527714A JP2019527714A (ja) | 2019-10-03 |
| JP2019527714A5 true JP2019527714A5 (enExample) | 2020-10-22 |
| JP7097027B2 JP7097027B2 (ja) | 2022-07-07 |
Family
ID=61160999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507125A Active JP7097027B2 (ja) | 2016-08-10 | 2017-08-10 | 自己免疫疾患の処置及び予防のための代謝物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20190167615A1 (enExample) |
| EP (1) | EP3496708B1 (enExample) |
| JP (1) | JP7097027B2 (enExample) |
| CN (1) | CN109562088A (enExample) |
| AU (1) | AU2017310263B2 (enExample) |
| CA (1) | CA3070939A1 (enExample) |
| ES (1) | ES3029611T3 (enExample) |
| WO (1) | WO2018027274A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| AU2019358875B2 (en) * | 2018-10-09 | 2025-08-21 | Monash University | Combination therapy for treatment and prevention of autoimmune and inflammatory diseases |
| CN109771404A (zh) * | 2019-02-28 | 2019-05-21 | 北京大学人民医院(北京大学第二临床医学院) | 丁酸在制备预防和/或治疗自身免疫性疾病药物中的应用 |
| EP3838283A1 (en) * | 2019-12-18 | 2021-06-23 | Mundus Sanus GmbH & Co. KG | Composition for use in the treatment of provocative diseases |
| US20230190942A1 (en) * | 2020-06-03 | 2023-06-22 | Corn Products Development, Inc. | Compositions of tri-substituted starch and methods for making and using the same |
| CN115068458B (zh) * | 2022-07-21 | 2023-12-12 | 哈尔滨医科大学 | 戊酸在制备防治糖尿病药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039703A (en) * | 1989-11-16 | 1991-08-13 | Breuer Richard I | Method for treating inflammatory bowel disorders |
| US5840860A (en) | 1993-11-17 | 1998-11-24 | Commonwealth Scientific And Industrial Research Organization | Fatty acid delivery system comprising a hydrolyzable bond |
| AUPQ132599A0 (en) | 1999-07-01 | 1999-07-22 | Commonwealth Scientific And Industrial Research Organisation | Nasogastric enteral formulations |
| DE102005046237A1 (de) * | 2005-09-28 | 2007-04-05 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen |
| WO2014145970A1 (en) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Modulation of regulatory t cells via g-coupled protein receptor 43 |
| AU2014342086A1 (en) | 2013-10-31 | 2016-05-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for inducing regulatory T-cell generation |
| US10226443B2 (en) * | 2014-10-16 | 2019-03-12 | New York University | Methods for treating psoriatic arthritis |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| US11065217B2 (en) * | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
| AU2019358875B2 (en) * | 2018-10-09 | 2025-08-21 | Monash University | Combination therapy for treatment and prevention of autoimmune and inflammatory diseases |
-
2017
- 2017-08-10 EP EP17838221.4A patent/EP3496708B1/en active Active
- 2017-08-10 CA CA3070939A patent/CA3070939A1/en active Pending
- 2017-08-10 JP JP2019507125A patent/JP7097027B2/ja active Active
- 2017-08-10 AU AU2017310263A patent/AU2017310263B2/en active Active
- 2017-08-10 WO PCT/AU2017/050845 patent/WO2018027274A1/en not_active Ceased
- 2017-08-10 US US16/323,726 patent/US20190167615A1/en not_active Abandoned
- 2017-08-10 CN CN201780049297.2A patent/CN109562088A/zh active Pending
- 2017-08-10 ES ES17838221T patent/ES3029611T3/es active Active
-
2021
- 2021-02-17 US US17/178,211 patent/US20210244692A1/en not_active Abandoned
-
2025
- 2025-04-10 US US19/175,560 patent/US20250295617A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527714A5 (enExample) | ||
| JP2016520590A (ja) | 治療薬および使用法 | |
| RU2016127232A (ru) | Антисмысловые композиции и способы их получения и применения | |
| CA2570184A1 (en) | Pharmaceutical compositions containing polyunsaturated fatty acid and at least one of an immunosuppressive agent or an antineoplastic agent | |
| AU2005253719A1 (en) | A pharmaceutical composition and its use | |
| CN114641293A (zh) | 一种fgfr抑制剂的用途 | |
| BRPI0812729A2 (pt) | materiais e métodos para tratamento e diagnósticos de distúrbios associados com estresse oxidativo | |
| JP2018529779A5 (enExample) | ||
| WO2015018344A1 (zh) | 穿心莲内酯在制备炎症性肠病的药物中的应用、穿心莲内酯肠溶靶向微丸及其制备方法 | |
| JP2016530279A5 (enExample) | ||
| JP2017512194A5 (enExample) | ||
| Kandula et al. | Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases | |
| JP2017519028A5 (enExample) | ||
| IL292770A (en) | Formulations and doses of pegylated uricase | |
| ES2982757T3 (es) | Acidos grasos electrofílicos tiolados reversiblemente protegidos como profármacos | |
| Avogaro et al. | Incretins and the cardiovascular system: bridging digestion with metabolism | |
| HRP20220999T1 (hr) | Terapija za ulcerozni kolitis zasnovana na oligonukleotidu | |
| JP2024504555A (ja) | 急性膵炎を予防及び治療するための薬物の製造におけるノルハルマンの使用 | |
| CN102058571A (zh) | 4-[(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸在制备用于预防及/或治疗肠粘连的药物中的应用 | |
| CN112315934A (zh) | 白头翁皂苷b4肠溶片的制备工艺 | |
| EP1251844B1 (en) | Laxative preparation containing l-arginine | |
| CN104983728B (zh) | 金合欢素在制备防治溃疡性结肠炎的药物或食品中的应用 | |
| CN103877084B (zh) | 一种治疗肛周溃疡的外用药物 | |
| CN109999044B (zh) | 一种含有醉茄素a的组合物及其应用 | |
| CN106727480A (zh) | Fex－3在制备抗肥胖症药物中的应用 |